Key Takeaways: Psoriasis remains undertreated in the US due to factors such as concerns about side effects, monitoring requirements, and the use of injectable treatments. TYK2 inhibitors, like orally administered deucravacitinib, represent a promising new treatment option for psoriasis. Numerous hurdles, including treatment costs, specialist availability, insurance coverage, and safety concerns need addressing for effective… Read More